<?xml version="1.0" encoding="UTF-8"?><rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0" xmlns:cc="http://cyber.law.harvard.edu/rss/creativeCommonsRssModule.html">
    <channel>
        <title><![CDATA[Stories by Dr. George Tetz on Medium]]></title>
        <description><![CDATA[Stories by Dr. George Tetz on Medium]]></description>
        <link>https://medium.com/@g.tetz?source=rss-dc94554fff1c------2</link>
        <image>
            <url>https://cdn-images-1.medium.com/fit/c/150/150/1*uPyKwHKkKuj8tUewfPUjUQ.jpeg</url>
            <title>Stories by Dr. George Tetz on Medium</title>
            <link>https://medium.com/@g.tetz?source=rss-dc94554fff1c------2</link>
        </image>
        <generator>Medium</generator>
        <lastBuildDate>Fri, 20 Nov 2026 07:27:02 GMT</lastBuildDate>
        <atom:link href="https://medium.com/@g.tetz/feed" rel="self" type="application/rss+xml"/>
        <webMaster><![CDATA[yourfriends@medium.com]]></webMaster>
        <atom:link href="http://medium.superfeedr.com/" rel="hub"/>
        <item>
            <title><![CDATA[Effective Antibiotic Selection for Lung Infections in Patients with Cystic Fibrosis: Myth or…]]></title>
            <link>https://medium.com/@g.tetz/effective-antibiotic-selection-for-lung-infections-in-patients-with-cystic-fibrosis-myth-or-fcce554787f1?source=rss-dc94554fff1c------2</link>
            <guid isPermaLink="false">https://medium.com/p/fcce554787f1</guid>
            <category><![CDATA[antibiotic-resistance]]></category>
            <category><![CDATA[atbfinder]]></category>
            <category><![CDATA[cystic-fibrosis]]></category>
            <category><![CDATA[infectious-disease]]></category>
            <category><![CDATA[antibiotics]]></category>
            <dc:creator><![CDATA[Dr. George Tetz]]></dc:creator>
            <pubDate>Fri, 17 Jul 2026 19:01:43 GMT</pubDate>
            <atom:updated>2026-07-17T19:29:43.784Z</atom:updated>
            <content:encoded><![CDATA[<h3>Effective Antibiotic Selection for Lung Infections in Patients with Cystic Fibrosis: Myth or Reality?</h3><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*0eAL4fpPTmamDrC9jrVWBQ.jpeg" /></figure><h4>When an infection is not eradicated in a patient with cystic fibrosis, the problem is not always a lack of antibiotic options — or simply antibiotic resistance. Often, the greater issue is that standard antibiotic susceptibility testing does not reproduce the conditions inside the lungs, where bacteria exist in dense, complex communities and are exposed to drug concentrations very different from those used in routine laboratory testing. This is the clinical gap AtbFinder test was developed to address: helping physicians and patients evaluate antibiotic options for difficult-to-treat, recurrent, biofilm-associated, and antibiotic-resistant infections when standard testing may not provide enough guidance. AtbFinder is a novel, rapid poly-phenotypic test that selects effective antibiotics using fundamentally new microbiological principles (<a href="https://atbfinder.com/">https://atbfinder.com/</a>).</h4><p>By George Tetz, MD, PhD</p><p>Cystic fibrosis (CF) is a chronic genetic condition affecting 40,000 adults and children in the United States (1). Mutations in the primary gene can lead to mucus thickening and becoming sticky in the lungs and other organs. This buildup of mucus doesn’t just clog the airways — it serves as a petri dish for infection-causing bacteria that is very difficult to eradicate.</p><p>Patients with CF go through repeated rounds of antibiotics, temporary improvement, and then need for the new antibiotic courses weeks or months later. Many patients wonder why repeated rounds of antibiotics are not working.</p><p>It’s a question I hear frequently from both physicians and patients. For many people with CF, chronic infection begins early, becoming one of the most serious complications of the disease. Even with advances in care, including CFTR modulator therapies that have improved outcomes for many patients, persistent lung infections remain a major clinical challenge (2, <a href="https://www.cdc.gov/cystic-fibrosis/about/index.html">https://www.cdc.gov/cystic-fibrosis/about/index.html</a>).</p><p>In many cases, these infections are labeled “<a href="https://substack.com/home/post/p-196735552">antibiotic-resistant</a>,” and certainly, resistance is part of the problem. But after working in microbiology and infectious diseases for decades, it’s clear that something else is also happening: Standard antibiotic susceptibility tests often fail to identify the antibiotics that will actually work in the lungs of patients with CF.</p><p>This is especially true in chronic, relapsing, biofilm-associated infections where bacteria behave very differently inside the patient than they do in the laboratory.</p><p>This is exactly why we developed created AtbFinder, a novel diagnostic test designed for difficult-to-treat patients that selects antibiotics that work when standard approaches fail. It helps physicians identify the right antibiotic for patients with complicated and resistant infections.</p><h3>Antibiotics not working cystic fibrosis?</h3><p>When people say antibiotics are not working in CF, they’re usually describing a very real and very frustrating cycle:</p><p>● Repeated pulmonary infections</p><p>● Worsening cough and mucus production</p><p>● Frequent antibiotic use</p><p>● Repeated hospitalizations</p><p>● Temporary improvement followed by relapse</p><p>Over time, infections become harder to suppress, and lung damage continues to progress.</p><p>One important distinction that often gets overlooked is the difference between a relapsing infection and a recurrent infection. A relapsing infection occurs when the original infection is never fully eradicated. The same organism survives treatment and later flares up again. A recurrent infection, by contrast, is a new infection that develops after the previous one has resolved.</p><p>In CF, relapsing infections are extremely common because microorganisms can persist deep within the lungs despite repeated antibiotic exposure.</p><h3>Why infections in cystic fibrosis are so difficult to treat</h3><p>CF lung infections are complex. The thick mucus the disease naturally produces creates an environment where microorganisms can settle, grow, and form persistent microbial communities.</p><p>Some of the most common pathogens include:</p><p>● <em>Pseudomonas aeruginosa</em></p><p>● <em>Staphylococcus aureus</em></p><p>● <em>Stenotrophomonas maltophilia</em></p><p>● <em>Achromobacter xylosoxidans</em></p><p>● Fungal organisms</p><p>It’s important to note that these infections are rarely caused by one organism. Bacteria and fungi coexist in polymicrobial communities that behave very differently from isolated microorganisms grown in the laboratory.</p><h3>Biofilms protect bacteria in the lungs</h3><p>In the lungs of patients with CF, microorganisms don’t simply float freely. They attach to surfaces and form structured microbial communities surrounded by a protective matrix known as a biofilm.</p><p>Within biofilms:</p><p>● Antibiotics penetrate poorly</p><p>● Microorganisms become dramatically more tolerant to treatment</p><p>● Bacteria protect one another from antibiotic exposure</p><p>Studies have shown that biofilm-associated bacteria may tolerate antibiotic concentrations hundreds or even thousands of times higher than free-floating bacteria tested under standard laboratory conditions. (3)</p><p>This explains why patients may initially improve on antibiotics but never fully eliminate the infection. Over time, repeated antibiotic exposure can further select for increasingly resistant organisms, creating a cycle of persistent infection, additional antibiotic use, and worsening treatment failure.</p><h3>The role of Pseudomonas aeruginosa and other persistent pathogens</h3><p>Among the most important pathogens in CF is <em>Pseudomonas aeruginosa</em> infection.</p><p>Once chronic <em>Pseudomonas</em> colonization becomes established, it can be extraordinarily difficult to eradicate. Research shows that it’s associated with faster lung function decline, more frequent pulmonary exacerbations, and increased hospitalization risk. (4)</p><p>These bacteria adapt to the lung environment, form highly resilient biofilms, and develop resistance mechanisms over time.</p><p>Again, CF lung infections often comprise polymicrobial ecosystems, which involve multiple bacterial and fungal organisms. These microbial interactions matter because neighboring organisms can negatively affect antibiotic response, protect one another, and contribute to treatment failure.</p><h3>Why antibiotics often fail in cystic fibrosis</h3><p>In many patients with CF, antibiotics appear to work temporarily but fail to fully eradicate the infection. One major reason is that standard laboratory testing doesn’t accurately capture what’s happening inside the lungs.</p><p>Conventional antimicrobial susceptibility testing was developed decades ago using simplified laboratory conditions. Typically, one isolated bacterium is grown in pure culture and exposed to antibiotics under standardized conditions. But in reality:</p><p>● Microorganisms exist in biofilms</p><p>● Infections are polymicrobial</p><p>● Mucus alters antibiotic activity</p><p>● Inflammation changes the local environment</p><p>Most standard susceptibility testing relies on antibiotic levels achievable in the bloodstream. But infections in CF occur in lung tissue and mucus, where antibiotic penetration may be very different.</p><p>As a result, an antibiotic that appears effective in laboratory testing may fail clinically simply because it never reaches adequate concentrations at the site of infection.</p><p>Traditional MIC-based testing evaluates bacteria in a free-floating, or planktonic, state. (5) Yet microorganisms in CF lungs primarily exist within biofilms, where they can tolerate antibiotic concentrations hundreds or even thousands of times higher than planktonic bacteria.</p><p>Genetic tests, such as PCR and sequencing-based resistance testing, also have limitations. While these tests can identify microorganisms or resistance genes, they don’t directly determine whether an antibiotic will successfully kill the infection inside the patient.</p><p>This is exactly why susceptibility results and clinical outcomes don’t always match. A laboratory report may suggest that an antibiotic should work, while the patient continues to decline clinically.</p><h3>A different approach to antibiotic selection in cystic fibrosis</h3><p>AtbFinder was developed to help address this gap between laboratory susceptibility testing and real clinical response.</p><p>Instead of testing only one isolated pathogen, AtbFinder evaluates antibiotic activity directly against the patient-derived polymicrobial biofilm community from the clinical specimen.</p><p>The test is designed to preserve important features of the infection environment, including:</p><p>● Polymicrobial structure</p><p>● Bacterial-fungal interactions</p><p>● Biofilm-associated tolerance</p><p>Another key distinction is that AtbFinder evaluates antibiotics at concentrations achievable in lung tissue rather than relying only on serum-based MIC thresholds.</p><p>AtbFinder also evaluates whether antibiotics work more effectively alone or in combination, which is particularly important in CF, where patients often receive multiple antibiotics simultaneously.</p><h3>Clinical findings</h3><p>In an investigator-initiated clinical study involving people with CF and chronic Pseudomonas aeruginosa colonization, antibiotics selected using AtbFinder produced notable results. (6)</p><p>After switching to AtbFinder-guided therapy:</p><p>● <em>Pseudomonas aeruginosa</em> was cleared in 81.8% of subsequent cultures</p><p>● Pulmonary exacerbations decreased substantially</p><p>● Lung function improved</p><p>● Systemic antibiotic use was reduced</p><h3>The Bottom Line</h3><p>Chronic lung infections in cystic fibrosis aren’t straightforward bacterial infections. They’re complex, biofilm-associated microbial ecosystems that often behave very differently from what standard laboratory testing predicts.</p><p>This helps explain why infections may persist even after repeated courses of antibiotics.</p><p>Antibiotic resistance is a real concern, but another major issue is our ability to accurately identify which antibiotics will truly work inside the lungs of patients with CF. This matters because chronic respiratory infections remain one of the primary drivers of morbidity and mortality in cystic fibrosis, despite major advances in treatment</p><p>As diagnostic tools continue to evolve, the future of treatment depends not only on developing new antibiotics but also on improving <em>how</em> we select the antibiotics we already have.</p><h3>Frequently Asked Questions</h3><h3>Why do infections keep coming back in cystic fibrosis?</h3><p>Many infections in cystic fibrosis are relapsing infections, meaning the original infection was never fully eradicated. Biofilms and polymicrobial communities allow microorganisms to persist in the lungs despite antibiotic treatment.</p><h3>What infections are common in cystic fibrosis patients?</h3><p>Common infections include <em>Pseudomonas aeruginosa</em>, <em>Staphylococcus aureus, Stenotrophomonas maltophilia</em>, <em>Achromobacter xylosoxidans</em>, and fungal infections.</p><h3>Why are antibiotics not working in cystic fibrosis?</h3><p>Antibiotics may fail because microorganisms in cystic fibrosis lungs exist within biofilms and polymicrobial communities that behave differently from isolated bacteria tested in the laboratory.</p><h3>Can cystic fibrosis infections become antibiotic-resistant?</h3><p>Yes. Repeated antibiotic exposure over time can select for multidrug-resistant organisms, making infections progressively harder to treat.</p><h3>How do doctors choose antibiotics for cystic fibrosis infections?</h3><p>Doctors typically rely on antimicrobial susceptibility testing, clinical response, and patient history. Newer approaches, such as functional testing against polymicrobial biofilms, aim to improve antibiotic selection in difficult-to-treat infections.</p><h3>References</h3><ol><li>Cystic Fibrosis Foundation. About Cystic Fibrosis. Cystic Fibrosis Foundation. Published 2025. <a href="https://www.cff.org/intro-cf/about-cystic-fibrosis">https://www.cff.org/intro-cf/about-cystic-fibrosis</a></li><li>Parisi GF, Terlizzi V, Manti S, et al. Cutting-Edge Advances in Cystic Fibrosis: From Gene Therapy to Personalized Medicine and Holistic Management. <em>Genes.</em> 2025;16(4):402. doi:10.3390/genes16040402</li><li>Mirghani R, Saba T, Khaliq H, et al. Biofilms: Formation, drug resistance and alternatives to conventional approaches. <em>AIMS Microbiology.</em> 2022;8(3):239–277. doi:10.3934/microbiol.2022019</li><li>Mehrin R, Anur Ramakrishnan GD. Association of Pseudomonas Infection with Disease Severity and Exacerbations in Non-cystic Fibrosis Bronchiectasis: A Retrospective Cross-sectional Study. J<em>ournal of Association of Pulmonologist of Tamil Nadu.</em> 2026;9(1):2–8. doi:10.4103/japt.japt_18_25</li><li>Kowalska-Krochmal B, Dudek-Wicher R. The Minimum Inhibitory Concentration of Antibiotics: Methods, Interpretation, Clinical Relevance. Pathogens. 2021;10(2):165. doi:10.3390/pathogens10020165</li><li>Tetz G, Kardava K, Vecherkovskaya M, et al. AtbFinder Diagnostic Test System Improves Optimal Selection of Antibiotic Therapy in Persons with Cystic Fibrosis. McAdam AJ, ed. <em>Journal of Clinical Microbiology. </em>2023;61(1). doi:10.1128/jcm.01558–22</li><li><a href="https://www.cff.org/">https://www.cff.org/</a></li></ol><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=fcce554787f1" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Antibiotic Resistance Is a Real Concern — Here’s How Personalized Antibiotic Selection Can Help]]></title>
            <link>https://medium.com/@g.tetz/antibiotic-resistance-is-a-real-concern-heres-how-personalized-antibiotic-selection-can-help-ac2acd269f46?source=rss-dc94554fff1c------2</link>
            <guid isPermaLink="false">https://medium.com/p/ac2acd269f46</guid>
            <dc:creator><![CDATA[Dr. George Tetz]]></dc:creator>
            <pubDate>Thu, 07 May 2026 19:38:31 GMT</pubDate>
            <atom:updated>2026-07-17T17:02:19.762Z</atom:updated>
            <content:encoded><![CDATA[<p>Antibiotic resistance is a misnomer. Here’s what it really means — and how novel diagnostic tests aimed to choose the right antibiotic can make the difference when infections don’t respond to treatment.</p><p>If you’ve ever dealt with an infection that just won’t go away, despite multiple rounds of antibiotics, your case isn’t an anomaly. In fact, it’s one of the most common and frustrating experiences for both patients and physicians. The same question comes up again and again: <em>“Why are antibiotics not helping me?”</em></p><p>In many cases, the answer seems clear: antibiotic resistance. And while antibiotic resistance is absolutely a growing global concern, it doesn’t always mean what many think it does. The biggest problem is that standard culture-based and genetic tests, while they provide important information, frequently fail to identify which antibiotic is most likely to work in more complex infections.</p><p>As a microbiologist, researcher, and physician who works with clinicians managing difficult infections, I’ve seen this pattern repeatedly. In complex, difficult-to-treat infections — especially those that are recurrent, biofilm-associated, or multidrug-resistant — standard antibiotic testing often doesn’t provide enough guidance to choose the right antibiotic.</p><p>This is exactly the gap I aimed to close with the AtbFinder, a new diagnostic test for antibiotic selection that helps physicians identify effective antibiotics when standard testing falls short and antibiotics are not working. More on this soon, but first, here’s what you need to know about antibiotic resistance.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*dx92TLCSinFXJhOoNhQtuw.jpeg" /></figure><h3>What does antibiotic resistance really mean?</h3><p>Antibiotic resistance is often described as bacteria becoming “immune” to antibiotics. In reality, according to the Centers for Disease Control and Prevention (CDC), it refers to the ability of microorganisms to survive or continue growing despite exposure to drugs designed to kill them (1) (2).</p><p>Bacteria and fungi employ several strategies to do this. Some prevent antibiotics from entering their cells. Others actively pump antibiotics out. Some modify the target that the drug is designed to attack.</p><p>These mechanisms are real, but there’s an important distinction that often gets overlooked: not all antibiotic-resistant infections are the same.</p><h3>Antibiotic-resistant vs. pan-resistant infections</h3><p>When people hear “antibiotic-resistant infection,” they very reasonably might think there aren’t any treatment options left to explore. But in reality, most infections are multidrug-resistant — not pan-resistant.</p><p><strong>Multidrug-resistant organisms are resistant to several antibiotics, but not all.</strong> <strong>Pan-resistant organisms, which are resistant to every available antibiotic, remain relatively rare </strong>(3).</p><p>That means that even when an infection is labeled as “resistant,” effective treatment options may still exist. The challenge? Identifying which treatments can help eradicate that specific group of bacteria.</p><h3>Why are antibiotics not working, even when current tests say they should?</h3><p>This is one of the most important, and perhaps least discussed, questions in infection treatment.</p><p>In theory, antibiotic selection should be straightforward. A sample is taken, bacteria are identified, and antibiotics are tested to see which ones inhibit growth.</p><p>But in real life, infections don’t behave as they do in the lab. This disconnect is reflected in the well-known “90–60 rule.” Even when bacteria are labeled “susceptible,” treatment works about 90% of the time. And even when labeled “resistant,” treatment can still succeed in roughly 60% of cases (4).</p><p>In other words, <strong>susceptibility does not always equal clinical success.</strong></p><h3>Why standard antibiotic tests often fail to predict real treatment success</h3><p>The reason is simple: laboratory testing doesn’t fully reflect what happens inside the body.</p><p>Standard tests isolate a single microorganism, place it in a controlled environment, and expose it to antibiotics. But infections in patients are <em>way</em> more complex than that.</p><p>At the site of infection, bacteria exist in communities (known as biofilms), interact with each other, and respond to the environment in ways that are difficult to replicate in the lab (5). These structured communities attach to surfaces such as tissues, catheters, or implants. They make it hard for antibiotics to penetrate, resulting in ultra-resilient microorganisms. Many chronic and recurrent infections, such as urinary tract infections (UTIs), lung infections, and infections contracted in hospital settings (such as sepsis) are often associated with biofilms.</p><p>Many difficult infections are polymicrobial, meaning multiple microorganisms are present at the same site (6). These organisms interact and support each other. Some produce substances that reduce antibiotic effectiveness, while others help create conditions that allow the entire community to survive.</p><p>In short, testing a single organism in isolation doesn’t capture these interactions.</p><h3>Why antibiotic concentration at the infection site matters</h3><p>Another key limitation of standard testing is how antibiotic concentrations are evaluated.</p><p>Laboratory thresholds are typically based on drug levels achievable in the bloodstream. But infections often occur in tissues where drug concentrations are much lower.</p><p>This includes:</p><ul><li>lungs</li><li>urinary tract</li><li>wounds</li><li>soft tissue</li></ul><p>This means that an antibiotic that <em>appears</em> to be effective in the lab may never reach sufficient levels at the site of infection. <strong>This is one of the main reasons an infection may not respond to antibiotics, even when the test results suggest it should.</strong></p><h3>What can doctors do if antibiotics fail?</h3><p>When antibiotics aren’t working, continuing the same approach can prolong infection and increase the risk of more severe health complications.</p><p>A more effective strategy is to step back and reassess:</p><ul><li>whether the infection is being evaluated under realistic conditions</li><li>whether polymicrobial interactions are being considered</li><li>whether antibiotics are reaching the infection site at effective concentrations</li><li>whether additional diagnostic testing could provide better guidance</li></ul><p>This shift away from the traditional trial-and-error approach is imperative for managing difficult infections.</p><h3>A different approach to antibiotic selection</h3><p>There needs to be more options for infections that don’t respond to antibiotics. After more than two decades of research, the gap became clear — antibiotic testing as it currently operates doesn’t reflect what’s actually happening on the cellular level in the patient.</p><p>AtbFinder was developed with this challenge in mind. It’s designed to help identify effective antibiotics when standard treatment isn’t working, particularly chronic, recurrent, and antibiotic-resistant infections (7).</p><p>Instead of testing a single isolated organism, <strong>AtbFinder evaluates how antibiotics perform against the full microbial community from the site of infection, including biofilms.</strong></p><p>It also considers how antibiotics behave at concentrations achievable in specific tissues, rather than relying only on blood-based assumptions. This allows for a more clinically relevant assessment of which antibiotics may be effective in real-world conditions.</p><p>This approach helps guide antibiotic selection in cases where patients have experienced repeated treatment failure and infections are not responding to antibiotics.</p><p>AtbFinder has been recognized at the national level for its innovation, including as a first-place winner in an FDA-organized competition in collaboration with Children’s National Hospital (8).</p><h3>The bottom line</h3><p>Antibiotic resistance is a real and growing concern. But in many cases, the reason antibiotics are not working isn’t just resistance alone — the right antibiotic can often do the job. Standard testing methods provide important information, but they fail to fully capture the complexity of how infections manifest in the human body.</p><p>If we want better outcomes, we need to move toward diagnostic approaches that reflect how infections behave in the body. Effective treatment depends on being able to choose the right antibiotic when it matters most.</p><h3>Frequently Asked Questions</h3><h3>Why is my infection not responding to antibiotics?</h3><p>An infection may not respond to antibiotics for several reasons, including biofilm formation, polymicrobial interactions, or insufficient antibiotic concentration at the site of infection. In many cases, the issue is not resistance alone, but difficulty identifying the most effective treatment.</p><h3>Can infections still respond if they’re labeled antibiotic-resistant?</h3><p>Yes. Even infections labeled as resistant can often respond to treatment. Most of these infections consist of multidrug-resistant organisms, which means they’re resistant to several drugs but not all. Very few infections are pan-resistant, or resistant to <em>all </em>antibiotics.</p><h3>How can AtbFinder help when antibiotics aren’t working?</h3><p>AtbFinder is based on a novel principle. It is a rapid polyphenotypic test that helps identify effective antibiotics by evaluating how they perform under conditions that more closely reflect real infections, including biofilms and site-specific drug exposure. This can improve antibiotic selection in difficult-to-treat infections.</p><h3>Is AtbFinder the same as standard culture-based or MIC testing?</h3><p>No. Standard culture and susceptibility (MIC) testing evaluates isolated primary pathogens under controlled laboratory conditions, typically in a free-floating state rather than within biofilms.</p><p>AtbFinder, by contrast, is designed to evaluate antibiotic activity against the full microbial community present at the site of infection, including biofilm-associated organisms. This allows for a more clinically relevant assessment of how antibiotics may perform in real-world conditions.</p><h3>Is AtbFinder a PCR or NGS test?</h3><p>No. PCR and next-generation sequencing (NGS) are designed to identify microorganisms or detect resistance genes. While these tools can provide valuable information, they do not directly assess how an infection will respond to a specific antibiotic.</p><p><strong>AtbFinder is a functional antibiotic selection test.</strong> It evaluates how antibiotics perform against a patient-derived microbial community, helping guide treatment decisions when infections are not responding to antibiotics.</p><h3>Can AtbFinder be used for recurrent UTI?</h3><p>Yes. AtbFinder includes a version specifically designed for recurrent or difficult-to-treat UTIs, especially when previous antibiotic rounds have failed or standard testing has not provided clear guidance.</p><h3>Can AtbFinder help with wound or respiratory infections?</h3><p>AtbFinder has a specific version designed for respiratory infections aimed to help with the antibiotic selection for difficult-to-treat respiratory infections where biofilms, polymicrobial communities, or multidrug resistance are suspected.</p><h3>Who can order AtbFinder?</h3><p>AtbFinder can be ordered or requested by a healthcare professional. Patients interested in the test can consult with their care team to determine whether it’s appropriate for their infection.</p><h3>How does AtbFinder differ from standard diagnostic methods?</h3><p>Different diagnostic methods answer different clinical questions. The key difference is whether the method evaluates isolated organisms, genetic markers, biofilms, or the functional behavior of the full microbial community.</p><h3>What is the difference between Culture + Microbroth Dilution / MIC / Disk-Diffusion Methods?</h3><p>Culture-based AST, including MIC and disk-diffusion methods, identifies how an isolated primary pathogen appears to respond to an antibiotic under standardized in vitro conditions. These conditions fail to replicate the real-life infection environment.</p><p>This approach does not assess microbial communities, biofilms, polymicrobial interactions, or tissue-level antibiotic exposure. As a result, an antibiotic reported as active by MIC testing may fail clinically if the real antibiotic concentration at the infection site is lower than the concentration used in the test.</p><h3>What is the purpose of molecular and genetic tests (PCR and NGS)?</h3><p>PCR and NGS identify which microorganisms or antibiotic-resistance genes are present in a sample. However, this information is often insufficient to select effective therapy for antibiotic-resistant infections.</p><p>These methods do not directly show which antibiotic will work clinically. The presence of an organism or resistance gene does not always translate into phenotypic resistance or treatment failure.</p><h3>Do Biofilm Inhibitory Concentration and Minimal Biofilm Eradication Concentration testing methods accurately represent real-life biofilm infections in patients?</h3><p>These methods partially address biofilm biology, but only for selected primary pathogens, not for the entire microbial community.</p><p>They remain primarily research-use approaches. They are not broadly clinically validated and do not assess real-life polymicrobial communities as they exist in patient samples.</p><h3>What sets AtbFinder apart from other tests?</h3><p>AtbFinder is designed to identify which antibiotics or antibiotic combinations functionally suppress the microbial community under clinically relevant conditions.</p><p>Unlike standard MIC-based testing, AtbFinder evaluates microbial communities, biofilm-associated behavior, and real-life polymicrobial interactions using antibiotic concentrations achievable at the site of infection.</p><h3>References</h3><ol><li>Centers for Disease Control and Prevention. 2019 Antibiotic Resistance Threats Report. Antimicrobial Resistance. Published May 7, 2024. <a href="https://www.cdc.gov/antimicrobial-resistance/data-research/threats/index.html">https://www.cdc.gov/antimicrobial-resistance/data-research/threats/index.html</a></li><li>Habboush Y, Guzman N. Antibiotic Resistance. National Library of Medicine. Published June 20, 2023. <a href="https://www.ncbi.nlm.nih.gov/books/NBK513277/">https://www.ncbi.nlm.nih.gov/books/NBK513277/</a></li><li>Antibiotic therapy for pan-drug-resistant infections. <em>infezioni in medicina.</em> 2022;30(4). doi:10.53854/liim-3004–6</li><li>Doern GV, Brecher SM. The Clinical Predictive Value (or Lack Thereof) of the Results of In Vitro Antimicrobial Susceptibility Tests. <em>Journal of Clinical Microbiology.</em> 2011;49(9 Supplement):S11-S14. doi:10.1128/jcm.00580–11</li><li>Zhao A, Sun J, Liu Y. Understanding bacterial biofilms: From definition to treatment strategies. <em>Frontiers in Cellular and Infection Microbiology.</em> 2023;13(1137947). doi:10.3389/fcimb.2023.1137947</li><li>Anju VT, Busi S, Imchen M, et al. Polymicrobial Infections and Biofilms: Clinical Significance and Eradication Strategies. <em>Antibiotics.</em> 2022;11(12):1731. doi:10.3390/antibiotics11121731</li><li>Tetz G, Kardava K, Vecherkovskaya M, et al. AtbFinder Diagnostic Test System Improves Optimal Selection of Antibiotic Therapy in Persons with Cystic Fibrosis. McAdam AJ, ed. <em>Journal of Clinical Microbiology.</em> 2023;61(1). doi:10.1128/jcm.01558–22</li><li>COVID-19-edition of pediatric medical device competition announces finalists | Children’s National Hospital. Children’s National Hospital. Published 2020. Accessed April 13, 2026. <a href="https://www.childrensnational.org/about-us/newsroom/2020/covid-19-edition-of-pediatric-medical-device-competition-announces-finalists">https://www.childrensnational.org/about-us/newsroom/2020/covid-19-edition-of-pediatric-medical-device-competition-announces-finalists</a></li></ol><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=ac2acd269f46" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Why Antibiotics Sometimes Fail — And How to Select the Right Treatment]]></title>
            <link>https://medium.com/@g.tetz/why-antibiotics-sometimes-fail-and-how-to-select-the-right-treatment-7d37d7de54ea?source=rss-dc94554fff1c------2</link>
            <guid isPermaLink="false">https://medium.com/p/7d37d7de54ea</guid>
            <category><![CDATA[antibiotic-resistance]]></category>
            <category><![CDATA[superbugs]]></category>
            <category><![CDATA[antibiotics]]></category>
            <category><![CDATA[recurrent-infections]]></category>
            <category><![CDATA[chronic-infection]]></category>
            <dc:creator><![CDATA[Dr. George Tetz]]></dc:creator>
            <pubDate>Thu, 16 Apr 2026 17:08:12 GMT</pubDate>
            <atom:updated>2026-07-17T17:07:14.908Z</atom:updated>
            <content:encoded><![CDATA[<p>When infections don’t respond to treatment, the issue isn’t always resistance — it’s often that the right antibiotic has yet to be selected. New approaches like AtbFinder aim to change that. AtbFinder is a novel rapid poly-phenotypic test that selects effective antibiotics using fundamentally new microbiological principles.</p><p>If your patients have ever dealt with an infection that just won’t go away despite repeated rounds of antibiotics, they know from personal experience just how frustrating and confusing it can be. But it can be equally frustrating for the provider as well.</p><p>As a microbiologist, researcher, and physician who helps other doctors manage hard-to-treat infections, I’m going to share something that is not yet widely understood in the medical community. <strong>The true crisis is not antibiotic resistance alone, but the failure of today’s antibiotic sensitivity tests to reliably identify antibiotics that actually work in patients.</strong></p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*dx92TLCSinFXJhOoNhQtuw.jpeg" /></figure><p>This is the clinical gap AtbFinder test was developed to address: helping physicians and patients evaluate antibiotic options for difficult-to-treat, recurrent, biofilm-associated, and antibiotic-resistant infections when standard testing may not provide enough guidance.</p><p>The truth is, very few pathogens (bacteria, fungi) are completely resistant to every available antibiotic. More often, antibiotics fail because existing diagnostic tests don’t always select the antibiotics that actually work for the patient.</p><p>Over the past 20 years, I’ve heard the same question from doctors and patients, usually after multiple rounds of treatment: <em>“Why are antibiotics not helping me?”</em></p><p>We tend to frame this problem as antibiotic resistance. Sure, antibiotic resistance is real and appears to be increasing. But that explanation alone doesn’t reflect what I see in clinical practice.</p><p>In reality, serious infections remain a major cause of death in the United States. According to national data from the Centers for Disease Control and Prevention (CDC), tens of thousands of people die each year from antibiotic-resistant infections, which include ESKAPE pathogens and superbugs (1). But when you look more broadly at severe infections overall, the numbers are even higher. Sepsis alone is associated with more than 350,000 deaths annually, while pneumonia and other serious infections account for hundreds of thousands more (2) (3) (4) (5).</p><p>It’s not because we lack antibiotics in this country, but because we don’t always identify the right antibiotic, or combination of antibiotics, for the specific infection and patient.</p><p>So when someone asks why their antibiotics are not working, or why the infection is not responding to antibiotics, the next step isn’t just to try another medication. A better approach would be to take a step back and ask: “<em>What additional tests can help find the right antibiotic?”</em></p><p>Before we dive into antibiotic testing, it’s important to understand <em>why </em>certain infections are harder to treat than others.</p><h3>What does it mean when your antibiotics are not working?</h3><p>When treatment fails, it’s natural to assume the bacteria are resistant to the medication, and sometimes that’s absolutely the case. But often, antibiotic failure is more complicated than that.</p><p>An infection can persist even when an antibiotic appears “active” in the lab. That’s because what happens in a petri dish isn’t always reflective of what’s happening inside the body.</p><p>Treatment can fail for several reasons in patients. For example, the antibiotic may not reach the infection site at a high enough concentration, the infection may involve multiple organisms working together, or the bacteria may be protected in ways that standard testing doesn’t capture. This is why people often experience what gets labeled as:</p><ul><li>Chronic infection</li><li>Persistent infection</li><li>Recurrent infection</li><li>Antibiotic-resistant infection</li><li>“No option” infection</li></ul><p>While these labels can be useful, they don’t always explain the underlying problem.</p><h3>Infections are complicated</h3><p>In medical training, infections are often presented as straightforward: identify the organism, match it with an antibiotic, and treat. But in reality, infections are rarely that simple.</p><p>Almost all “complicated” infections involve more than one microorganism. Different bacteria, sometimes along with fungi, can coexist at the same site, forming complex communities that behave very differently from a single organism in isolation (as you’d see it in a lab). These communities can support each other’s survival, protecting each other from antibiotics and making treatment more difficult.</p><p>Another major factor is biofilm formation. Instead of floating freely, microorganisms often attach to surfaces and produce a protective matrix. Within these biofilms, they become dramatically more tolerant to antibiotics — sometimes requiring concentrations hundreds or even thousands of times higher than what would normally be effective (6).</p><p>At the same time, not all pathogens involved in an infection are easily detectable. Some don’t grow well in standard laboratory conditions, which means part of the infection may go undetected (7).</p><p>Even when bacteria are successfully identified, they can behave differently outside of the body. Lab conditions can’t fully recreate what’s happening inside a patient, so test results don’t always match what happens in real life (8).</p><p>And finally, antibiotics don’t always distribute evenly throughout the body. A drug that works well in the bloodstream may not reach sufficient levels in your lungs, urinary tract, or soft tissues, for example. So an antibiotic can look effective on paper but still fail where it matters most.</p><p>All of these factors contribute to a simple but important reality: The infection we treat in the lab is not always the infection the patient actually has.</p><h3>Why standard laboratory tests can be misleading</h3><p>When an infection is not responding to antibiotics, clinicians rely on laboratory testing to guide the next step. These tests are essential, but they have limitations that are often overlooked.</p><p>Traditional <strong>phenotypic tests</strong> measure how bacteria respond to antibiotics under controlled conditions. These methods have been used for decades and remain the foundation for choosing an antibiotic.</p><p>But they typically evaluate one organism at a time, ignoring that many infections involve multiple species. They test bacteria in a free-floating state rather than within biofilms. And they interpret results based on antibiotic concentrations achievable in blood, not necessarily at the actual site of infection.</p><p>There is also a timing issue. In serious infections, waiting several days for results can mean that patients continue receiving ineffective treatment while their condition worsens.</p><p>The limitations of these tests are reflected in what’s known as the “90–60 rule.” In simple terms, even when a bacterium is labeled “susceptible,” treatment works as expected only about 90% of the time. And surprisingly, even when it’s labeled “resistant,” treatment can still work in roughly 60% of cases (9).</p><p>That’s a significant gap, and it highlights a key problem: standard laboratory categories don’t always predict what actually happens in the patient.</p><p><strong>Molecular tests</strong>, on the other hand, offer a different approach by identifying pathogens or resistance genes more quickly. These can be valuable tools, especially in urgent situations.</p><p>But they answer a different question. They tell us what might be present, not necessarily what will respond to treatment.</p><p><strong>Identifying a resistance gene does not always mean that resistance is active in that patient.</strong> And identifying a pathogen does not guarantee that a particular antibiotic will be effective in the patient’s body (10). So while these tests are useful, they often stop short of selecting the antibiotics that would really work for the patient.</p><h3>Clinical situations where infections are not responding to antibiotics</h3><p>Treating doctors and families often notice when something isn’t right. A loved one is receiving treatment, but the condition isn’t improving. The same concerns come up again and again. Some of these include:</p><p><em>Why is pneumonia not responding to antibiotics?</em></p><p><em>Why is sepsis not improving despite treatment?</em></p><p><em>Why does the infection keep coming back after antibiotics?</em></p><p>These are not rare scenarios — they’re common occurrences in hospitals, especially in patients with complex medical conditions, such as ventilator-associated pneumonia, cystic fibrosis, or in immunocompromised patients.</p><p>In these situations, simply changing antibiotics or increasing doses may not be enough. Without better insight into what is actually happening at the infection site, treatment can become a repetitious (and defeating) cycle of trial and error.</p><h3>What does a better test look like?</h3><p>If we want to improve health outcomes, we need to rethink how we evaluate infections.</p><p>A more useful diagnostic approach? <strong>Start by looking at the infection as a whole rather than focusing on a single “primary” or “lead” pathogen.</strong> It would consider how microorganisms interact, how they behave within biofilms, and how antibiotics perform under conditions that resemble the patient’s actual body.</p><p>It would also take into account where the infection is located. The concentration of an antibiotic in the lungs or urinary tract differs significantly from its level in the bloodstream. Testing should reflect those differences.</p><p>Another equally important factor is speed. In serious infections, waiting days for results can limit the ability to intervene effectively. Faster, more relevant data could change treatment decisions earlier in the course of illness.</p><p>Finally, a better test would evaluate a broader range of antibiotics, including combinations when needed, rather than limiting the analysis to a small predefined panel.</p><p>In other words, we need diagnostics that move closer to real-life treatments — not further away from them.</p><h3>How AtbFinder selects antibiotics against antibiotic-resistant microorganisms</h3><p>AtbFinder is an alternative approach to antibiotic selection, specifically in cases where standard susceptibility-guided treatment doesn’t lead to clinical resolution. This test was developed with this exact challenge in mind: how to choose the right antibiotic when standard treatment is not working. It helps identify effective antibiotics for resistant, chronic, persistent, recurrent, and hard-to-treat infections.</p><p>Unlike traditional methods, AtbFinder evaluates antibiotics against all microorganisms present at the infection site, including “primary” pathogen and supporting microorganisms, rather than isolating a single pathogen. It also incorporates biofilm conditions, recognizing that many infections exist in this protected state and maintaining the patient-mediated microbial “memory.”</p><p>Another key difference is how antibiotic exposure is modeled. Instead of relying only on blood-based assumptions, AtbFinder tests antibiotics at concentrations that reflect what is actually achievable in specific tissues, such as the lungs, urinary tract, or wounds.</p><p>The test is also designed to be both exhaustive and fast. It evaluates a large panel of antibiotics, often between 90 and 180, and delivers results within hours rather than days.</p><p>Clinical studies have shown that this method can improve antibiotic selection in difficult-to-treat infections, including pulmonary infections and chronic urinary tract infections (11) (12).</p><h3>The Bottom Line</h3><p>When antibiotics are not working, it’s easy to fall into a pattern of trying one medication after another. But without more information from better testing, that approach can prolong the problem rather than solve it.</p><p>A more effective step is to pause and reassess. Consider asking yourself, and your care team, the following questions:</p><ol><li>Is the infection being evaluated in a way that reflects how it actually behaves in the body?</li><li>Are we relying on tests that may not capture the full picture?</li><li>What additional tests can help find the right antibiotic?</li></ol><p>The goal is to move away from testing systems that oversimplify the biology of complex infections and toward approaches that better capture what’s happening at the site of infection.</p><p>This is exactly the gap newer technologies, such as AtbFinder, are designed to address. In fact, this approach has been recognized at a national level, including as a first-place winner in an FDA-organized competition in collaboration with Children’s National Hospital (13).</p><p><strong>The future of infection treatment depends not only on developing new antibiotics, but on learning how to select the right existing antibiotics more accurately, more rapidly, and in ways that mirror real-life conditions.</strong></p><p>This is the major gap that current testing often fails to close, and the gap that better diagnostics must address.</p><h3>FAQ</h3><h3>What should I do if antibiotics did not help?</h3><p>If antibiotics are not working, the next step is not simply switching medications. It’s important to reassess how the infection is being evaluated and whether additional testing can help identify the right antibiotic based on real-life infection conditions.</p><h3>What can doctors do if antibiotics fail?</h3><p>When antibiotics fail, clinicians should consider whether standard susceptibility testing reflects the actual infection environment. More advanced diagnostic approaches may help improve antibiotic selection, especially in complex or persistent infections.</p><h3>Why is my infection not responding to antibiotics?</h3><p>An infection may not respond to antibiotics for several reasons. It may involve multiple microorganisms, exist within biofilms, or require antibiotic concentrations that are not achieved at the site of infection.</p><h3>How does AtbFinder help identify effective antibiotics?</h3><p>AtbFinder is designed to address one of the most important questions in infection treatment: <strong>can an antibiotic, at the concentration that actually reaches the site of infection, eliminate the infection?</strong></p><p>Instead of relying only on standard laboratory conditions, AtbFinder evaluates how antibiotics perform under conditions that more closely reflect what happens in the body. This includes testing at tissue-level antibiotic concentrations — such as those found in the lungs, urinary tract, blood, skin, or wounds — rather than relying only on blood-based assumptions.</p><p>It also assesses how antibiotics act against all microorganisms present at the infection site, including within biofilms and microbial communities, rather than testing a single isolated pathogen.</p><p>By combining these factors, AtbFinder helps improve antibiotic selection in cases where infections are resistant, chronic, persistent, or not responding to standard treatment.</p><h3>How does AtbFinder differ from standard diagnostic methods?</h3><p>Different diagnostic methods answer different clinical questions. The key difference is whether the method evaluates isolated organisms, genetic markers, biofilms, or the functional behavior of the full microbial community.</p><h3>What is the difference between Culture + Microbroth Dilution / MIC / Disk-Diffusion Methods?</h3><p>Culture-based AST, including MIC and disk-diffusion methods, identifies how an isolated primary pathogen appears to respond to an antibiotic under standardized in vitro conditions. These conditions fail to replicate the real-life infection environment.</p><p>This approach does not assess microbial communities, biofilms, polymicrobial interactions, or tissue-level antibiotic exposure. As a result, an antibiotic reported as active by MIC testing may fail clinically if the real antibiotic concentration at the infection site is lower than the concentration used in the test.</p><h3>What is the purpose of molecular and genetic tests (PCR and NGS)?</h3><p>PCR and NGS identify which microorganisms or antibiotic-resistance genes are present in a sample. However, this information is often insufficient to select effective therapy for antibiotic-resistant infections.</p><p>These methods do not directly show which antibiotic will work clinically. The presence of an organism or resistance gene does not always translate into phenotypic resistance or treatment failure.</p><h3>Do Biofilm Inhibitory Concentration and Minimal Biofilm Eradication Concentration testing methods accurately represent real-life biofilm infections in patients?</h3><p>These methods partially address biofilm biology, but only for selected primary pathogens, not for the entire microbial community.</p><p>They remain primarily research-use approaches. They are not broadly clinically validated and do not assess real-life polymicrobial communities as they exist in patient samples.</p><h3>What sets AtbFinder apart from other tests?</h3><p>AtbFinder is designed to identify which antibiotics or antibiotic combinations functionally suppress the microbial community under clinically relevant conditions.</p><p>Unlike standard MIC-based testing, AtbFinder evaluates microbial communities, biofilm-associated behavior, and real-life polymicrobial interactions using antibiotic concentrations achievable at the site of infection.</p><h3>References</h3><ol><li>Centers for Disease Control and Prevention. 2019 Antibiotic Resistance Threats Report. Antimicrobial Resistance. Published May 7, 2024. <a href="https://www.cdc.gov/antimicrobial-resistance/data-research/threats/index.html">https://www.cdc.gov/antimicrobial-resistance/data-research/threats/index.html</a></li><li>Rhee C, Jones TM, Hamad Y, et al. Prevalence, Underlying Causes, and Preventability of Sepsis-Associated Mortality in US Acute Care Hospitals. <em>JAMA Network Open. </em>2019;2(2):e187571. doi:10.1001/jamanetworkopen.2018.7571</li><li>Carey MG, Valcin EK, Lent D, White M. Nursing Care for the Initial Resuscitation of Severe Sepsis Patients. <em>Critical Care Nursing Clinics of North America. </em>2021;33(3):263–274. doi:10.1016/j.cnc.2021.05.003</li><li>La Via L, Ferlito S, Di Modica MS, et al. The Global Impact of Sepsis: Epidemiology, Recognition, Management, and Health System Challenges. <em>Epidemiologia.</em> 2026;7(1):20. doi:10.3390/epidemiologia7010020</li><li>CDC. FastStats — Pneumonia. Centers for Disease Control and Prevention. Published 2019. <a href="https://www.cdc.gov/nchs/fastats/pneumonia.htm">https://www.cdc.gov/nchs/fastats/pneumonia.htm</a></li><li>Thöming JG, Häussler S. Pseudomonas aeruginosa Is More Tolerant Under Biofilm Than Under Planktonic Growth Conditions: A Multi-Isolate Survey.<em> Frontiers in Cellular and Infection Microbiology.</em> 2022;12. doi:10.3389/fcimb.2022.851784</li><li>Tetz G, Tetz V, Vecherkovskaya M. Genomic characterization and assessment of the virulence and antibiotic resistance of the novel species Paenibacillus sp. strain VT-400, a potentially pathogenic bacterium in the oral cavity of patients with hematological malignancies. <em>Gut Pathogens.</em> 2016;8(1). doi:10.1186/s13099–016–0089–1</li><li>Tetz V, Tetz G. Novel prokaryotic system employing previously unknown nucleic acids-based receptors. <em>Microbial Cell Factories</em>. 2022;21(1). doi:10.1186/s12934–022–01923–0</li><li>Doern GV, Brecher SM. The Clinical Predictive Value (or Lack Thereof) of the Results of In Vitro Antimicrobial Susceptibility Tests. <em>Journal of Clinical Microbiology</em>. 2011;49(9 Supplement):S11-S14. doi:10.1128/jcm.00580–11</li><li>Tetz G, Tetz V. Overcoming Antibiotic Resistance with Novel Paradigms of Antibiotic Selection. <em>Microorganisms.</em> 2022;10(12):2383. doi:10.3390/microorganisms10122383</li><li>Tetz G, Kardava K, Vecherkovskaya M, et al. AtbFinder Diagnostic Test System Improves Optimal Selection of Antibiotic Therapy in Persons with Cystic Fibrosis. McAdam AJ, ed. <em>Journal of Clinical Microbiology.</em> 2023;61(1). doi:10.1128/jcm.01558–22</li><li>Tetz GV, Kardava KM, Vecherkovskaya MF, Tsifansky MD, Tetz VV. Treatment of chronic relapsing urinary tract infection with antibiotics selected by AtbFinder. <em>Urology Case Reports.</em> 2022;46:102312. doi:10.1016/j.eucr.2022.102312</li><li>COVID-19-edition of pediatric medical device competition announces finalists | Children’s National Hospital. Children’s National Hospital. Published 2020. Accessed April 13, 2026. <a href="https://www.childrensnational.org/about-us/newsroom/2020/covid-19-edition-of-pediatric-medical-device-competition-announces-finalists">https://www.childrensnational.org/about-us/newsroom/2020/covid-19-edition-of-pediatric-medical-device-competition-announces-finalists</a></li></ol><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=7d37d7de54ea" width="1" height="1" alt="">]]></content:encoded>
        </item>
    </channel>
</rss>